Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib-Reference-Cited by-同舟云学术

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib

Published:2017-08-29 Issue:9 Volume:117 Page:1278-1285
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Joensuu Heikki,Blay Jean-Yves,Comandone Alessandro,Martin-Broto Javier,Fumagalli Elena,Grignani Giovanni,Del Muro Xavier Garcia,Adenis Antoine,Valverde Claudia,Pousa Antonio Lopez,Bouché Olivier,Italiano Antoine,Bauer Sebastian,Barone Carlo,Weiss Claudia,Crippa Stefania,Camozzi Maura,Castellana Ramon,Le Cesne Axel

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2017290.pdf

Reference34 articles.

1. Adenis A, Blay JY, Bui-Nguyen B, Bouche O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blésius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A (2014) Masitinib in advanced gastrointestinal stromal tumour (GIST) after failure of imatinib: a randomized controlled open-label study. Ann Oncol 25: 1762–1769.

2. Agaimy A, Wunsch PH, Hofstaedter F, Blaszyk H, Rummele P, Gaumann A, Dietmaier W, Hartmann A (2007) Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31: 113–120.

3. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182–4190.

4. Artinyan A, Kim J, Soriano P, Chow W, Bhatia S, Ellenhorn JD (2008) Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities. Cancer Epidemiol Biomarkers Prev 17: 2194–2201.

5. Bauer S, Joensuu H (2015) Emerging agents for the treatment of advanced, imatinib resistant gastrointestinal stromal tumors: current status and future directions. Drugs 75: 1323–1324.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular pathology of gastrointestinal stromal tumors;Diagnostic Molecular Pathology;2024

2. A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors;PLOS ONE;2023-08-30

3. Advances in Drug Therapy for Gastrointestinal Stromal Tumour;Current Medicinal Chemistry;2023-05-05

4. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours;Gastric Cancer;2023-03-13

5. N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies;RSC Advances;2023